F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
IPO Year: 2016
Exchange: NASDAQ
Website: f-star.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2022 | $35.00 → $7.00 | Buy → Neutral | H.C. Wainwright |
| 11/18/2021 | $15.00 | Buy | Ladenburg Thalmann |
| 8/17/2021 | $39.00 → $35.00 | Outperform | SVB Leerink |
| 7/8/2021 | $39.00 | Outperform | SVB Leerink |